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ABSTRACT.
Purpose: To evaluate the cost-eﬀectiveness of ultrathin Descemet stripping automated
endothelial keratoplasty (UT-DSAEK) versus standard DSAEK.
Methods: A cost-eﬀectiveness analysis using data from a multicentre randomized clinical
trial was performed. The time horizon was 12 months postoperatively. Sixty-four eyes of 64
patients with Fuchs’ endothelial dystrophy were included and randomized to UT-DSAEK
(n = 33) or DSAEK (n = 31). Relevant resources from healthcare and societal perspectives
were included inthecostanalysis.Quality-adjusted lifeyears (QALYs)weredeterminedusing
theHealthUtilities IndexMark3questionnaire.Themainoutcomewas the incremental cost-
eﬀectiveness ratio (ICER; incremental societal costs per QALY).
Results: Societal costs were €9431 (US$11 586) for UT-DSAEK and €9110 (US
$11 192) forDSAEK.Quality-adjusted life years (QALYs) were 0.74 in both groups. The
ICER indicated inferiority ofUT-DSAEK.The cost-eﬀectiveness probability ranged from
37% to 42%, assuming the maximum acceptable ICER ranged from €2500–€80 000 (US
$3071–US$98 280) per QALY. Additional analyses were performed omitting one UT-
DSAEK patient who required a regraft [ICER €9057 (US$11 127) per QALY, cost-
eﬀectiveness probability: 44–62%] and correcting QALYs for an imbalance in baseline
utilities [ICER €23 827 (US$29 271) per QALY, cost-eﬀectiveness probability: 36–
59%]. Furthermore, the ICER was €2101 (US$2581) per patient with clinical improve-
ment in best spectacle-corrected visual acuity (≥0.2 logMAR) and €3274 (US$4022) per
patient with clinical improvement in National Eye Institute Visual Functioning
Questionnaire-25 composite score (≥10 points).
Conclusion: The base case analysis favoured DSAEK, since costs of UT-DSAEK were
higher while QALYs were comparable. However, additional analyses revealed no
preference for UT-DSAEK or DSAEK. Further cost-eﬀectiveness studies are required to
reduce uncertainty.
Key words: corneal transplantation – cost-eﬀectiveness – costs – Descemet stripping automated
endothelial keratoplasty – Fuchs’ endothelial dystrophy – quality-adjusted life years – ultrathin
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Fuchs’ endothelial dystrophy (FED) is
the most common indication for cor-
neal transplantation. (Park et al. 2015).
Without treatment, many patients with
FED would become visually impaired
and accrue substantial costs to society
(The Lewin Group 2013).
Endothelial keratoplasty (EK),
involving selective transplantation of
posterior corneal layers, accounts for
over 90% of keratoplasties in FED
patients (Eye Bank Association of
America (EBAA) 2016; Dickman et al.
2016b). Descemet stripping automated
endothelial keratoplasty (DSAEK) is
the most frequently performed subtype
of EK (Park et al. 2015). Previous cost-
eﬀectiveness analyses demonstrated
that DSAEK and other (less advanced)
EK techniques were cost-eﬀective com-
pared to traditional full-thickness pen-
etrating keratoplasty (Beauchemin
et al. 2010; van den Biggelaar et al.
2012; Bose et al. 2013; Prabhu et al.
2013). In recent years, innovative EK
techniques using thinner corneal grafts
have emerged aiming to further
improve visual outcomes (Neﬀ et al.
2011). These include Descemet mem-
brane endothelial keratoplasty
(DMEK) and ultrathin DSAEK (UT-
DSAEK). While DMEK is technically
challenging and considered unsuitable
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for eyes with diﬃcult anatomy, UT-
DSAEK may provide results superior
to DSAEK using grafts that are easier
to prepare and manipulate than
DMEK grafts (Busin et al. 2012,
2013). A recent cost-eﬀectiveness study
demonstrated that DMEK was cost-
eﬀective compared to DSAEK from a
societal perspective (Gibbons et al.
2019).
Our study group recently reported
a multicentre randomized controlled
clinical trial (RCT) that compared
visual and refractive outcomes,
endothelial cell loss and complications
up to 12 months after UT-DSAEK or
DSAEK in FED patients. Ultrathin
Descemet stripping automated
endothelial keratoplasty resulted in
faster and better visual recovery, with
similar hyperopic shift, endothelial
cell loss and complication proﬁle
(Dickman et al. 2016a). Despite
encouraging clinical outcomes, imple-
mentation of UT-DSAEK may be
associated with increased costs from
a healthcare perspective. Possible
causes include longer surgery duration
and additional surgical procedures
due to graft dislocations or graft
failure. A cost-eﬀectiveness analysis
is required to support health policy-
makers in making evidence-based
decisions on allocation of scarce
healthcare resources. Many countries
have published guidelines on the pre-
ferred methods for conducting and
reporting cost-eﬀectiveness analyses.
These guidelines advocate quality-ad-
justed life years (QALYs) as the
primary measure of eﬀectiveness
(Drummond et al. 2015). Quality-ad-
justed life years (QALYs) are based
on generic health-related quality of
life (HRQL) measured at various
points in time using designated ques-
tionnaires. They incorporate both
changes in quality of life and life
expectancy. Quality-adjusted life years
(QALYs) are applied in all ﬁelds in
health care to investigate the cost-
eﬀectiveness of diﬀerent types of
healthcare interventions in diﬀerent
populations in a standardized manner.
Using the cost per QALY, health
policymakers may allocate limited
healthcare resources based on a pre-
deﬁned willingness to pay per QALY.
In this paper, we report a trial-based
cost-eﬀectiveness analysis of UT-
DSAEK versus DSAEK, from a soci-
etal perspective.
Materials and Methods
This economic evaluation was con-
ducted alongside a multicentre RCT at
four tertiary medical centres in the
Netherlands (Maastricht University
Medical Center+, The Rotterdam Eye
Hospital, University Medical Center
Utrecht and University Medical Center
Groningen). The study was performed
from a healthcare and societal perspec-
tive with a time horizon of 12 months,
starting from the day of surgery. Insti-
tutional review boards of all centres
approved the study before start of
patient recruitment. Participants were
recruited between June 2013 and April
2014 and gave written informed con-
sent. The study was conducted in accor-
dance with the principles of the
Declaration of Helsinki and good clin-
ical practice guidelines and was regis-
tered in a clinical trial register (www.tria
lregister.nl, identiﬁer NTR 3104).
Study procedures
The study population and study proce-
dures were described previously
(Dickman et al. 2016a). Brieﬂy, FED
patients who required corneal trans-
plantation due to irreversible corneal
endothelial dysfunction were recruited.
One eye per patient was included in the
study. Inclusion in the economic evalu-
ation also depended on completion of
quality-of-life questionnaires during at
least one follow-up visit. The sample
size was based on best spectacle-cor-
rected visual acuity (BSCVA), the pri-
mary outcome of the study.
Patients were randomized to UT-
DSAEK or DSAEK. All tissues were
precut by a cornea bank (Euro Tissue
Bank, Beverwijk, the Netherlands), and
treatment allocation was disclosed
solely to the cornea bank. Methods
for selection, preservation and dissec-
tion were identical for UT-DSAEK
and DSAEK corneas.
Surgery was performed by experi-
enced cornea surgeons using identi-
cal techniques for UT-DSAEK and
DSAEK. Patients were either pseu-
dophakic or underwent combined pha-
coemulsiﬁcation with intraocular lens
implantation and corneal transplanta-
tion (triple procedure). In cases of graft
detachment, a rebubbling procedure
was performed to reposition and stabi-
lize the graft. In cases of graft failure, a
regraft procedure was performed.
Cost analysis
The economic evaluation was per-
formed in accordance with national
guidelines (Hakkaart-van Roijen et al.
2015). All relevant resources consumed
from a societal and healthcare perspec-
tive were included. To determine costs,
resource use volumes were multiplied
with unit cost prices including sales
taxes. Costs were converted to 2014
Euros (€) using the Consumer Price
Index (Centraal Bureau voor de Statis-
tiek 2018) and to US$ using the 2014
purchasing power parity for gross
domestic product (PPP for GDP; US
$1.00 = €0.814) (Organisation for Eco-
nomic Co-operation and Development
2018).
Data on resource use were obtained
through hospital registries and self-
administered patient questionnaires.
Hospital-based resources included
operating room times, corneas, hospi-
tal admissions, outpatient visits and
medication use. Patient-reported
resources included general practitioner
visits, home care, visual aids (including
spectacles), travel and productivity
loss. The patient-reported resource use
questionnaire had a 3-month recall
time period and was completed 3, 6
and 12 months postoperatively. All
recurring patient-reported resource
use reported at 12 months was doubled
to account for the lack of data on
resource use at 9 months postopera-
tively.
Operating room times were valued
using integral cost prices provided by
Maastricht University Medical Cen-
ter+. While operating room cost prices
may vary between diﬀerent centres,
cost prices of only one centre were
chosen to calculate costs for all patients
in order to avoid bias when using
diﬀerent cost prices for patients
included in diﬀerent centres. Cost
prices included costs of personnel,
standard materials and equipment,
and overhead. Two costs drivers were
applicable: general operating room
costs (cost per minute spent in the
operating room) and ophthalmology
costs (cost per minute spent in surgery).
Few patients required secondary pro-
cedures for which procedure times were
unknown, and reimbursement prices,
also provided by Maastricht University
Medical Center+, were used instead.
Prices of (precut) donor corneas were
not available. Therefore, previously
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reported cornea prices were used (van
den Biggelaar et al. 2011). Standardized
prices provided by national guidelines
for cost analysis were used to value
hospital admissions, outpatient visits,
general practitioner visits, home care,
travel and productivity loss (Hakkaart-
van Roijen et al. 2015). Spectacle costs
were based on average costs provided by
an optometry market research report
(Q&AResearch&Consultancy&Terra
2011). Other visual aids (loupes, televi-
sion spectacles) were valued based on
market prices (Worldwidevision, Ois-
terwijk, the Netherlands). Prescription
medication was valued using reimburse-
ment prices (including a standard phar-
macy service fee) (Zorginstituut
Nederland 2018), while over-the-coun-
ter medication (0.1% sodium hyaluro-
nate eye drops in one patient) was
valued using producer-recommended
prices (URSAPHARM Benelux BV,
Helmond, the Netherlands).
Effectiveness
Eﬀectiveness was based on generic
HRQL (main outcome), vision-related
quality of life and BSCVA (secondary
outcomes).
Health-related quality of life
(HRQL) was determined using the
Health Utilities Index Mark 3 question-
naire (HUI3; Health Utilities Inc.,
Hamilton, ON, Canada), which is one
of few HRQL questionnaires that
includes questions about visual func-
tioning. TheHUI3 assesses eight dimen-
sions of health (vision, hearing, speech,
ambulation, dexterity, emotion, cogni-
tion and pain) with ﬁve to six levels per
dimension. Consequently, the HUI3 is
capable of distinguishing 972 000 dif-
ferent health states. Each health state is
associated with a utility score, which
ranges from 0.36 (health state worse
than death) to 1.00 (perfect health)
(Horsman et al. 2003). Utility scores
were used to calculate QALYs for each
patient separately by determining the
area under the curve of subsequent
utility measurements, assuming linear
changes in utilities over time (Manca
et al. 2005).
Vision-related quality of life was
measured with the National Eye Insti-
tute Visual Functioning Questionnaire-
25 (NEI VFQ-25, National Eye Insti-
tute, Bethesda, MD, USA). The NEI
VFQ-25 is a 26-item questionnaire (25
vision items and 1 general health item)
evaluating the impact of visual impair-
ment on quality of life (Mangione et al.
2001). Thirteen optional questions are
available to increase accuracy.
Responses on the items are scored 0 to
100, and item subset scores can be
averaged to obtain 12 subscales (e.g.
general health, distance activities and
driving). Higher scores represent better
visual functioning. In addition, all sub-
scales, excluding the general health
scale, can be averaged to obtain a
composite score (Mangione et al. 2001).
Best spectacle-corrected visual acuity
(BSCVA) was assessed using a 100%
contrast Early Treatment Diabetic
RetinopathyStudy chart (VectorVision,
Greenville, OH, USA) at 4 m distance
and expressed in logarithm of the mini-
mum angle of resolution (logMAR).
Outcome assessors were blinded to allo-
cated treatment at all follow-up visits.
All data were collected during the
preoperative visit and 3, 6 and
12 months after surgery.
Cost-effectiveness analyses
To assess cost-eﬀectiveness, the incre-
mental cost-eﬀectiveness ratio (ICER)
was calculated, which expresses the
incremental costs of UT-DSAEK for
each additional unit of the health eﬀect.
Uncertainty in incremental costs and
eﬀects was assessed using non-paramet-
ric bootstrapping with 1000 replications
(Microsoft Excel 2010 for Windows;
Microsoft, Redmond, WA, USA).
Bootstrap results were plotted on cost-
eﬀectiveness planes. Cost-eﬀectiveness
acceptability curves were constructed to
estimate the probability that UT-
DSAEK was cost-eﬀective based on a
range of ceiling ratios for the ICER.
Ceiling ratios reﬂect the maximum price
health policymakers are willing to pay
for an additional QALY. In the Nether-
lands, the ceiling ratio for conditions
with limited burden of disease is €20 000
(US$24 570) per QALY (Zwaap et al.
2015). No ceiling ratios for other types
of (clinical or patient-reported) out-
comes exist.
In the base case analysis, cost-eﬀec-
tiveness was based on QALYs and
costs from a societal perspective over
12-month follow-up.
Secondary analyses were performed
using alternative eﬀectiveness measures
and costs from a healthcare perspec-
tive. Eﬀectiveness measures included
clinical improvement in BSCVA (≥0.2
logMAR improvement) and NEI
VFQ-25 composite score (≥10-point
improvement) (Rosser et al. 2003;
Lindblad & Clemons 2005). One UT-
DSAEK patient suﬀered primary graft
failure and required a regraft during
follow-up. Graft failure is a rare and
costly event that may distort the
cost-eﬀectiveness analysis results in a
relatively small study population.
Therefore, a post hoc secondary anal-
ysis was performed, identical to the
base case analysis, excluding the
patient in question.
In a sensitivity analysis, the base
case analysis was repeated with a cor-
rection for baseline utility diﬀerences
by adding the mean diﬀerence in base-
line utility between treatment groups to
all utility measurements in the treat-
ment group with the lower mean
baseline utility, resulting in equal base-
line values. In addition, to explore
uncertainty in operating room costs,
two-one-way sensitivity analyses were
performed in which operating room
costs were increased and decreased
by 25%.
Statistical analysis
Analyses were performed according to
the intention-to-treat principle. Incom-
plete cost and eﬀectiveness data were
assumed missing at random and
imputed using multiple imputation
with predictive mean matching (mice
package; R version 3.3.2 for Windows,
The R Foundation, Vienna, Austria).
The imputation regression model
included the following covariates:
treatment group, age, sex and study
centre. Twenty imputation sets were
obtained using 100 iterations per impu-
tation. Imputation sets were analysed
separately, and the results were pooled.
Diﬀerences between treatment
groups were statistically tested with
independent samples t-tests. Paired
samples t-tests were used to test diﬀer-
ences between preoperative and post-
operative measurements (IBM SPSS
Statistics Version 23.0 for Windows;
IBM, Armonk, NY, USA). A p
value < 0.05 was considered statisti-
cally signiﬁcant.
Results
Of 187 patients assessed for eligibility
for participation, 117 did not meet




patients were randomized to DSAEK
(n = 32) and UT-DSAEK (n = 34). All
patients received the allocated treat-
ment. In the UT-DSAEK group, one
patient suﬀered primary graft failure
following intraoperative graft trauma
unrelated to the intervention and this
patient chose to withdraw from the
study. In the DSAEK group, one
patient deceased after 3-month follow-
up (unrelated to the intervention).
Neither patient completed postopera-
tive quality-of-life questionnaires
resulting in exclusion from the eco-
nomic evaluation. Consequently, 64
eyes of 64 patients were included in
the economic evaluation (DSAEK 31
patients, UT-DSAEK 33 patients).
Twenty-seven DSAEK and 27 UT-
DSAEK patients completed all ques-
tionnaires; the baseline questionnaire
was missing in one patient in both
treatment groups; one postoperative
questionnaire was missing in one
DSAEK and two UT-DSAEK
patients; two postoperative question-
naires were missing in two DSAEK
patients and three UT-DSAEK
patients.
Mean patient age was 70.2 years
[standard deviation (SD): 10.0] and
70.7 years (SD: 10.1) in the UT-
DSAEK and DSAEK group, respec-
tively. There were more males in the
DSAEK group (58%) than in the UT-
DSAEK group (42%). The frequency
of triple procedures was comparable
[UT-DSAEK 9 (27%), DSAEK 10
(32%)]. In the UT-DSAEK group, ﬁve
patients (15%) underwent corneal
transplantation of the non-study eye
during follow-up, in three patients
(9%) combined with cataract surgery.
In the DSAEK group, six patients
(19%) underwent second-eye corneal
transplantation during follow-up, com-
bined with cataract surgery in four
patients (13%). One DSAEK patient
(3%) underwent second-eye cataract
surgery without a corneal transplanta-
tion. Costs directly related to second-
eye surgery were not included in the
cost analysis. In both treatment
groups, seven patients (DSAEK 23%,
UT-DSAEK 21%) had paid employ-
ment.
The following percentages of data
were missing and imputed for DSAEK
and UT-DSAEK, respectively: HUI3
5.4% and 7.9%, BSCVA 3.2% and
3.8%, VFQ-25 7.0% and 9.8%, and
cost data 5.3% and 8.2%.
Costs
Mean resource use and costs are
reported in Table 1. Societal costs
averaged €9431 (US$11 586) in the
UT-DSAEK group and €9110 (US
$11 192) in the DSAEK group, that is
a €321 (US$394) diﬀerence. From a
healthcare perspective, costs averaged
€7881 (US$9682) and €7565 (US$9294)
for UT-DSAEK and DSAEK, respec-
tively (diﬀerence €316 [US$388]).
Notably, one patient in the UT-
DSAEK group suﬀered graft failure
shortly after surgery and required a
regraft procedure.
Effectiveness
Eﬀectiveness outcomes are shown in
Table 2 and Figure 1.
Mean utility increased signiﬁcantly
after UT-DSAEK [0.14 increase, stan-
dard error of the mean (SE): 0.04,
p < 0.001, paired t-test] and DSAEK
(0.11 increase, SE: 0.04, p = 0.003,
Table 1. Mean resource use and costs from a healthcare and societal perspective (in 2014 €) of DSAEK and UT-DSAEK
Cost per unit (€)
Resource use, mean (SE) Costs, mean (SE), €
DSAEK (n = 31) UT-DSAEK (n = 33) DSAEK (n = 31) UT-DSAEK (n = 33)
Healthcare sector
Corneal transplantation OR time
General operating room costs 12.14/min 97 (4.1) 99 (4.1) 1183 (50.0) 1202 (49.8)
Ophthalmology costs 3.61/min 71 (3.6) 73 (3.5) 258 (12.9) 262 (12.5)
Secondary procedures† Variable Variable 161 (61.6) 189 (79.9)
Cornea 4067/cornea 1.00 1.03 4067 4190
Hospital admission
Day care 276/day 0.90 (0.1) 0.94 (0.1) 249 (29.6) 259 (26.7)
Inpatient days 642/day 0.48 (0.2) 0.67 (0.2) 311 (106.8) 428 (133.0)
Outpatient visits
Ophthalmologist 163/visit 7.1 (0.3) 7.2 (0.2) 1152 (51.8) 1181 (38.9)
Other specialists 163/visit 0.10 (0.1) 0 (0) 16 (11.7) 0 (2.7)
Medication Variable Variable 151 (17.5) 126 (6.6)
General practitioner visits Variable Variable 10 (6.8) 23 (12.4)
Home care 50/hr 0.15 (0.1) 0.42 (0.2) 7 (7.3) 21 (11.6)
Subtotal 7565 (182) 7881 (293)
Patient and family costs
Visual aids Variable Variable 329 (59.3) 199 (49.7)
Travel costs Variable Variable 28 (11.5) 13 (4.1)
Subtotal 357 (61) 211 (50)
Other sectors
Productivity costs (paid work) 34.75/hr 34.2 (18.5) 38.5 (20.0) 1188 (643.4) 1338 (696.3)
Subtotal 1188 (643) 1338 (696)
Total costs from societal perspective 9110 (710) 9431 (736)
DSAEK = Descemet stripping automated endothelial keratoplasty, UT-DSAEK = ultrathin Descemet stripping automated endothelial keratoplasty,
OR = operating room, SE = standard error of the mean.
†Includes rebubblings, corneal regrafts and other related (non-surgical) procedures.
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paired t-test). However, there were no
signiﬁcant diﬀerences in utilities
between treatment groups. Mean
QALYs were identical (0.74, SE: 0.04,
p = 0.912, independent samples t-test).
Excluding patients who underwent
corneal transplantation and/or cataract
surgery in the non-study eye during
follow-up resulted in QALYs of 0.71
(UT-DSAEK) and 0.75 (DSAEK).
Mean BSCVA and NEI VFQ-25
composite score increased signiﬁcantly
in both groups. In addition, mean
BSCVA was signiﬁcantly better in the
UT-DSAEK group at all follow-up
measurements. While the mean NEI
VFQ-25 composite score at 12 months
postoperatively was slightly higher in
the UT-DSAEK group (85.9, SE: 1.7,
versus 83.5, SE: 2.4), the diﬀerence was
not statistically signiﬁcant (p = 0.383,
independent samples t-test).
Cost-effectiveness
The results of the cost-eﬀectiveness
analyses are listed in Table 3.
In the base case analysis from a
societal perspective, costs of UT-
DSAEK were €321 (US$394) higher
while QALYs were comparable. Based
on the ICER point estimate, UT-
DSAEK was inferior to DSAEK. The
data were bootstrapped, and the results
were plotted in a cost-eﬀectiveness
plane (Figure 2) and cost-eﬀectiveness
acceptability curve (Figure 3). The
probability that UT-DSAEK was
cost-eﬀective compared to DSAEK
ranged from 37% to 42% assuming
the ICER ceiling ratio ranged from
€2500 (US$3071) to €80 000 (US
$98 280) per QALY. Assuming health
policymakers in the Netherlands are
willing to pay €20 000 (US$24 570) per
QALY, the cost-eﬀectiveness probabil-
ity was 37% (Zwaap et al. 2015).
Secondary analyses revealed that the
ICER was €2101 (US$2581) per patient
with clinical improvement in BSCVA
and €3274 (US$4022) per patient with
clinical improvement in NEI VFQ-25
composite score.
A post hoc secondary analysis
excluding an UT-DSAEK patient who
required a regraft showed that societal
costs were €146 (US$179) higher and
QALYs were 0.02 higher in the UT-
DSAEK group. The ICER was €9057
(US$11 127) per QALY, and the cost-
eﬀectiveness probability was 54%.
A sensitivity analysis showed that
QALYs were 0.02 higher in the UT-
DSAEK group after correcting for
baseline utility diﬀerences. The ICER
was €23 827 (US$29 271) per QALY.
The cost-eﬀectiveness probability was
49%. Finally, two sensitivity analyses
that explored the eﬀects of increasing
or decreasing operating room costs by
25% revealed no important diﬀerences
in the cost-eﬀectiveness probability of
UT-DSAEK.
Discussion
This trial-based cost-eﬀectiveness anal-
ysis evaluated the cost-eﬀectiveness of
UT-DSAEK versus DSAEK. In the
base case analysis from a societal
perspective, UT-DSAEK was slightly
more costly than DSAEK and compa-
rably eﬀective. Uncertainty analysis
revealed a 37% probability that UT-
DSAEK was cost-eﬀective compared
to DSAEK. Secondary analyses from a
healthcare perspective using clinical
outcomes resulted in seemingly favour-
able ICERs. However, health policy-
makers have not deﬁned the willingness
to pay for outcomes other than
QALYs, making it diﬃcult to interpret
these ICERs (Zwaap et al. 2015). A
post hoc secondary analysis was per-
formed because one UT-DSAEK
patient suﬀered primary graft failure
and required a regraft, which aﬀected
cost-eﬀectiveness outcomes. The rea-
soning was that, due to the limited
sample size, the incidence of graft
failure in this study likely does not
reﬂect the true incidence of graft fail-
ure. The ICER improved to €9057 (US
$11 127) per QALY with a 54% cost-
eﬀectiveness probability.
Table 2. Measures of eﬀectiveness at baseline and 3, 6 and 12 months after DSAEK or UT-
DSAEK
DSAEK (n = 31) UT-DSAEK (n = 33) p Value
HUI3 utility, mean (SE)
T0 0.64 (0.04) 0.62 (0.04) 0.734
T1 0.78 (0.04) 0.74 (0.05) 0.500
T2 0.75 (0.04) 0.76 (0.04) 0.906
T3 0.74 (0.05) 0.76 (0.05) 0.802
Diﬀerence (T3–T0) 0.11 (0.04)† 0.14 (0.04)‡ 0.466
Quality-adjusted life years, mean (SE) 0.74 (0.04) 0.74 (0.04) 0.912
BSCVA, mean (SE), logMAR
T0 0.35 (0.04) 0.37 (0.03) 0.773
T1 0.28 (0.03) 0.17 (0.02) 0.001
T2 0.24 (0.02) 0.14 (0.02) 0.001
T3 0.19 (0.02) 0.13 (0.02) 0.037
Diﬀerence (T3–T0) 0.16 (0.04)‡ 0.24 (0.03)‡ 0.136
NEI VFQ-25 composite score, mean (SE)
T0 70.2 (2.7) 69.6 (3.0) 0.885
T1 80.9 (2.6) 82.0 (2.0) 0.738
T2 82.4 (2.1) 83.5 (1.9) 0.697
T3 83.5 (2.4) 85.9 (1.7) 0.410
Diﬀerence (T3–T0) 13.3 (2.2)‡ 16.3 (2.6)‡ 0.383
BSCVA = best spectacle-corrected visual acuity, DSAEK = Descemet stripping automated
endothelial keratoplasty, HUI3 = Health Utilities Index Mark 3, logMAR = logarithm of the
minimum angle of resolution, NEI VFQ-25 = National Eye Institute Visual Functioning
Questionnaire-25, SE = standard error of the mean, T0 = baseline, T1 = 3 months postopera-
tively, T2 = 6 months postoperatively, T3 = 12 months postoperatively, UT-DSAEK = ultrathin
Descemet stripping automated endothelial keratoplasty.
†p Value = 0.003.








Baseline 3 months 6 months 12 months
DSAEK UT-DSAEK
Fig. 1. Health-related quality of life (utility) at
baseline and 3, 6 and 12 months after DSAEK
or UT-DSAEK. DSAEK = Descemet strip-
ping automated endothelial keratoplasty, UT-




Utilities were measured with a well-
validated generic HRQL questionnaire.
A clear improvement in generic HRQL
was demonstrated following either cor-
neal transplantation technique; how-
ever, the observation that UT-DSAEK
led to better visual acuity outcomes
compared to DSAEK did not result in
HRQL diﬀerences detectable by the
HRQL questionnaire. Generic HRQL
questionnaires are necessary to enable
calculation of QALYs. However,
because generic HRQL questionnaire
aims to assess an individual’s overall
health status, these questionnaires do
not explore the various health
dimensions in as much detail as for
instance a disease-speciﬁc question-
naire would. As a result, generic
HRQL questionnaires are less respon-
sive to small improvements in speciﬁc
dimensions of health. Disease-speciﬁc
quality-of-life questionnaires (such as
the NEI VFQ-25) might be more
responsive, but do not allow for calcu-
lation of QALYs (Drummond et al.
2015). It should be noted that a num-
ber of patients in the study underwent
second-eye surgery during follow-up
(corneal transplantation, cataract sur-
gery or both). In the UT-DSAEK
group, 15% of patients underwent
second-eye surgery, compared to 22%
of patients in the DSAEK group.
However, a subgroup analysis of
patients that did not undergo second-
eye surgery during follow-up showed
that this imbalance did not appear to
lead to more favourable QALYs in the
DSAEK group (data not shown).
This study aimed to accurately esti-
mate incremental costs of UT-DSAEK
by including all types of resource use
potentially aﬀected, for example pro-
ductivity losses. Nonetheless, a number
of study limitations may have aﬀected
Table 3. Results of the cost-eﬀectiveness analyses of DSAEK versus UT-DSAEK
Mean costs (€) Mean eﬀects Incremental cost-eﬀectiveness ratio (€)
Probability cost-eﬀective at ceiling ratio
€ 2500/5000/10 000/20 000/50 000/80 000 (%)
Base case analysis
QALYs and costs from societal perspective, 12-month follow-up
DSAEK 9110 0.74 ― ―
UT-DSAEK 9431 0.74 Inferior 37/37/37/37/40/42
Secondary analyses
Clinical improvement in BSCVA (0.2 logMAR or more) and costs from healthcare perspective, 12-month follow-up
DSAEK 7565 0.36 ― ―
UT-DSAEK 7881 0.52 2101/patient 57/74/83/87/88/88
Clinical improvement in NEI VFQ-25 composite score (≥10 points) and costs from healthcare perspective, 12-month follow-up
DSAEK 7565 0.50 ― ―
UT-DSAEK 7881 0.60 3274/patient 43/58/68/73/75/75
QALYs and costs from societal perspective excluding a patient with regraft, 12-month follow-up
DSAEK 9110 0.74 ― ―
UT-DSAEK 9256 0.76 9057/QALY 44/45/48/54/60/62
Sensitivity analyses
QALYs, corrected for baseline utility diﬀerence, and costs from societal perspective, 12-month follow-up
DSAEK 9110 0.74 ― ―
UT-DSAEK 9431 0.76 23 827/QALY 36/39/42/49/58/59
QALYs and costs from societal perspective, 12-month follow-up, operating room costs increased by 25%
DSAEK 9490 0.74 ― ―
UT-DSAEK 9844 0.74 Inferior 35/34/35/36/41/43
QALYs and costs from societal perspective, 12-month follow-up, operating room costs decreased by 25%
DSAEK 8730 0.74 ― ―
UT-DSAEK 9018 0.74 Inferior 38/37/37/39/42/42
BSCVA = best spectacle-corrected visual acuity, DSAEK = Descemet stripping automated endothelial keratoplasty, logMAR = logarithm of the
minimum angle of resolution, NEI VFQ-25 = National Eye Institute Visual Functioning Questionnaire-25, QALYs = quality-adjusted life years, UT-
















Fig. 2. Cost-eﬀectiveness plane showing the incremental costs from a societal perspective (y-axis)
and incremental QALYs (x-axis) of treatment with UT-DSAEK compared to DSAEK within a
time horizon of 12 months postoperatively. Each data point represents one bootstrapped estimate
of incremental costs and QALYs. DSAEK = Descemet stripping automated endothelial kerato-




accuracy of the cost analysis. First, use
of a self-administered patient question-
naire may have resulted in under-
reporting of non-hospital-based
resource use. In addition, patient-re-
ported resource use was not measured
at 9 months postoperatively. However,
this was corrected for by doubling
patient-reported resource use measured
at 12 months postoperatively. As
shown in Tables S1 and S2, patient-
reported resource use was comparable
at 6 and 12 months postoperatively. It
is therefore not expected that the
results have been biased by the miss-
ingness of these data. Second, the time
horizon of this study was 12 months
postoperatively. Little is known about
possible diﬀerences in long-term graft
survival between UT-DSAEK and
DSAEK and its impact on cost-eﬀec-
tiveness. The longest follow-up after
UT-DSAEK was reported in a non-
comparative study by Busin et al.
(2013), showing that graft survival
after 2 years was 96.2%. In compar-
ison, reported graft survival rates
2 years after DSAEK were 80.0–
90.7% (Hjortdal et al. 2013; Ang et al.
2016; Heinzelmann et al. 2016). One
study found a survival rate of 94%
3 years after DSAEK (Price et al.
2013). Lastly, the cost price of corneas
was uncertain. In this study, all corneas
were precut by a cornea bank. Methods
for preparing precut UT-DSAEK and
DSAEK corneas and numbers of lost
donor tissues in both groups were
similar (Dickman et al. 2016a). There-
fore, cost diﬀerences were not expected
and previously reported costs were
used instead (van den Biggelaar et al.
2011).
The sample size calculation for the
study was based on BSCVA as the
primary outcome. Indeed, sample size
calculations in clinical trial-based eco-
nomic evaluations are commonly based
on clinical outcomes rather than eco-
nomic outcomes. However, in economic
evaluations, the aim is not to test a
predeﬁned hypothesis using traditional
statistical methods, but rather to sup-
port health policymakers in making
reimbursement decisions. To achieve
this, economic evaluations estimate
average costs and eﬀects of the com-
parative interventions along with indi-
cators of uncertainty, commonly
represented by bootstrap analyses and
cost-eﬀectiveness acceptability curves
displaying the probability of one treat-
ment being cost-eﬀective compared to
alternatives (Claxton 1999; O’Sullivan
et al. 2005; Petrou & Gray 2011).
Although this study was performed
in the Netherlands and the cost anal-
ysis was based on national cost prices,
the results can be translated to other
countries. To improve transferability of
the results, volumes of resource use
were reported separately for most
resources. In addition, the PPP for
GDP can convert costs to other cur-
rencies and correct for diﬀerences in
price levels between countries (Organ-
isation for Economic Co-operation and
Development 2018).
Health policymakers should con-
sider both clinical and economic out-
comes when deciding on the allocation
of scarce healthcare resources. While
UT-DSAEK leads to improved visual
acuity, the base case analysis of this
economic evaluation demonstrated a
slight preference for DSAEK over UT-
DSAEK. Further secondary and sensi-
tivity analyses did not show a clear
preference for either treatment. Addi-
tional studies are required to reduce
uncertainty in the reported outcomes.
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